Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Haleon PLC ( (GB:HLN) ) is now available.
Haleon PLC announced its half-year results for 2025, revealing a 10% increase in the interim dividend to 2.2 pence per share, reflecting its policy to distribute approximately one-third of the prior year’s full-year dividend. This decision underscores Haleon’s commitment to growing its ordinary dividend in line with adjusted earnings, subject to market conditions and board approval. The results presentation by the CEO and CFO will be available online, followed by a Q&A session, indicating transparency and engagement with stakeholders.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects its strong financial performance and positive earnings call insights, which highlight growth in emerging markets and innovation. Mixed technical indicators suggest caution, while valuation metrics indicate moderate fair value.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a range of products across six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 23,069,477
Technical Sentiment Signal: Hold
Current Market Cap: £32.99B
For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.